The ORCA-2 Trial Has Completed Target Enrollment

The ORCA-2 Trial Has Completed Target Enrollment

About ORCA-2 study

Cytisinicline is a natural, plant-based drug that is being researched in the United States as an aid to smoking cessation.  The ORCA-2 study is a randomized, placebo-controlled Phase 3 clinical trial evaluating the effectiveness and safety of cytisinicline.

ORCA-2 is now enrolled with more than 750 adults from the following cities who currently smoke cigarettes daily and intend to quit smoking.

  • Atlanta, Georgia

  • Boston, Massachusetts

  • Dallas, Texas

  • Evansville, Indiana

  • Kansas City, Missouri

  • Knoxville, Tennessee

  • Las Vegas, Nevada

  • Lexington, Kentucky

  • Miami, Florida

  • Mobile, Alabama

  • Mt. Pleasant, South Carolina

  • New Orleans, Louisiana

  • Norfolk, Virginia

  • Phoenix, Arizona

  • Raleigh, North Carolina

  • Rochester, New York

  • Wichita, Kansas